News

Pharmabiz4d
Cellectar’s IopofosineI 131 receives US FDA breakthrough therapy designation for treating Waldenstrom macroglobulinemia
Cellectar’s IopofosineI 131 receives US FDA breakthrough therapy designation for treating Waldenstrom macroglobulinemia: Florham Park, New Jersey Friday, June 6, 2025, 17:00 Hrs ...
TipRanks on MSN5d
Cellectar Biosciences Raises $2.5 Million via Stock Sale
Cellectar Biosciences ( ($CLRB) ) just unveiled an update. On June 5, 2025, Cellectar Biosciences entered into agreements to raise $2.5 million ...
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...
FDA Designation Sparks Rally For This Biotech
Real-time index price for Nasdaq Global Market Composite Index (NQGM), along with buy or sell indicators, analysis, charts, ...
Cellectar Biosciences stock soars on FDA breakthrough designation
Shares of Cellectar Biosciences Inc (NASDAQ:CLRB) surged 63.5% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its cancer ...
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained
Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following ...
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.5%, while Spain's IBEX 35 Index fell 0.2%. London ...
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance ...